TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Nkarta Therapeutics IPO

Nkarta Therapeutics IPO

nkartatx.comHealthcare

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer.

Learn more about Nkarta Therapeutics stock
Updated on: Jun 12, 2022
Register for Details

For more details on financing and valuation for Nkarta Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Nkarta Therapeutics's ticker symbol?

NKTX

What is Nkarta Therapeutics's stock price?

3.37 as of 3/24/23

Learn more about Nkarta Therapeutics

Forge green plus iconForge green minus icon

What is Nkarta Therapeutics funding to date?

Nkarta Therapeutics has raised $125MM.
Forge green plus iconForge green minus icon

When was Nkarta Therapeutics founded?

Nkarta Therapeutics was founded in 2015.

Trending Companies

Frequently Asked Questions